☆ 4.0 Article

Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival

ARCHIVES OF ENDOCRINOLOGY METABOLISM (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis

Yee-Ming Melody Cheung et al.

Summary: The development of immune-related thyroid dysfunction during immune checkpoint inhibitor therapy is associated with improved overall survival and progression free survival for cancer patients. This suggests that thyroid immune-related adverse events can be used as a surrogate marker for clinical response to ICIs.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹

Article Oncology

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma

Kennedy Yao Yi Ng et al.

Summary: A study on advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitors shows an association between immune-related adverse events and efficacy, with more severe events linked to better prognosis. Prompt use of systemic corticosteroids in patients experiencing adverse events is crucial for ensuring optimal long-term outcomes.

LIVER CANCER (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-Induced Endocrinopathy: A Prospective Study

Artak Labadzhyan et al.

Summary: This study prospectively evaluated the impact of endocrine autoimmunity on the development of immune checkpoint inhibitor (ICI)-induced adverse events (ERAE) and overall survival (OS). ERAE occurred in 14 patients, with hypothyroidism being the most common. The presence of antibodies was significantly associated with ERAE. The presence of ERAE was associated with a more favorable OS.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹

Review Oncology

Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors-A systematic review and meta-analysis

Syed Hussaini et al.

Summary: The study showed a positive correlation between the occurrence of immune-related adverse events and treatment efficacy (ORR, PFS, OS) in patients treated with immune checkpoint inhibitors for various solid malignancies. However, grade 3 or 4 adverse events resulted in better objective response rate but worse overall survival.

CANCER TREATMENT REVIEWS (2021)

添加到收藏夹

Article Endocrinology & Metabolism

2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021

Summary: The American Diabetes Association's Standards of Medical Care in Diabetes provides clinical practice recommendations, treatment goals, guidelines, and tools for evaluating care quality. It is updated annually by a multidisciplinary expert committee, and readers are invited to comment on the standards at professional.diabetes.org/SOC.

DIABETES CARE (2021)

添加到收藏夹

Article Oncology

Clinical-Bladder cancer Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors

Vincent T. Ma et al.

Summary: The study aimed to determine the clinical outcomes of patients with advanced genitourinary malignancies treated with ICIs. Results showed that increased frequency and higher grades of irAEs were associated with better treatment response, while the presence of liver metastases was linked to a poorer response.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

添加到收藏夹

Article Oncology

Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors

Li Zhong et al.

Summary: This study demonstrates that irAEs triggered by ICIs, especially in the skin, endocrine organs, or gastrointestinal tract, can predict significant survival benefits for patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Agnese Paderi et al.

Summary: It has been found that the presence of immune-related adverse events (irAEs) is associated with better clinical response to immunotherapy. Specifically, thyroid dysfunction and skin reactions are correlated with the efficacy of immune-checkpoint inhibitors in metastatic renal cell cancer patients. Additionally, experiencing multiple irAEs in a single patient is linked to improved tumor response.

CANCERS (2021)

添加到收藏夹

Review Medicine, General & Internal

Endocrine complications of immunotherapies: a review

Rosie Hattersley et al.

Summary: The use of immune checkpoint inhibitors in cancer treatment has increased significantly in the past decade, leading to improved survival rates but also resulting in adverse endocrine effects in around 10% of patients. Thyroid disease and hypophysitis are the most commonly encountered, highlighting the importance of patient and clinician education for early recognition and management of these immune-related complications.

CLINICAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Dylan J. Martini et al.

Summary: The study revealed early onset immune-related adverse events (irAEs) are associated with significantly improved clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Specifically, endocrine irAEs, particularly thyroid irAEs, were found to significantly impact clinical outcomes. These findings suggest that irAEs, especially thyroid irAEs, may serve as clinical biomarkers of clinical outcomes in mRCC patients treated with ICIs.

ONCOLOGIST (2021)

添加到收藏夹

Review Medicine, General & Internal

Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis

Xiaoxiang Zhou et al.

BMC MEDICINE (2020)

添加到收藏夹

Article Oncology

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study

Tomoko Kobayashi et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Review Oncology

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors

Xiao-Hui Jia et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Review Oncology

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Filipe Martins et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Endocrinology & Metabolism

2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism

George J. Kahaly et al.

EUROPEAN THYROID JOURNAL (2018)

添加到收藏夹

Article Oncology

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

I. Puzanov et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline

Maria Fleseriu et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline

Stefan R. Bornstein et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)

添加到收藏夹

Article Endocrinology & Metabolism

CLINICAL PRACTICE GUIDELINES FOR HYPOTHYROIDISM IN ADULTS: COSPONSORED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND THE AMERICAN THYROID ASSOCIATION

Jeffrey R. Garber et al.

ENDOCRINE PRACTICE (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.